Open Peer Review on Qeios

HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine

National Cancer Institute

Source

National Cancer Institute. <u>HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine</u>. NCI Thesaurus. Code C82661.

A synthetic peptide cancer vaccine consisting of HLA-A2-restricted peptides derived from glioma-associated antigens (GAA) with potential immunostimulating and antineoplastic activities. Upon administration, HLA-A2-restricted synthetic glioma antigen peptides vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CT L) response against tumor cells expressing the corresponding GAAs, resulting in glioma tumor cell lysis. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity.